GERN
$0.99
Geron
($.06)
(5.71%)
GERN
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($0.09)
Revenue:  $0.11 Mil
Thursday
Jun 11
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when GERN reports earnings?
Beat
Meet
Miss

Where is GERN's stock price going from here?
Up
Flat
Down
Stock chart of GERN
Analysts
Summary of analysts' recommendations for GERN
Score
Grade
Pivots
Resistance
$1.14
$1.11
$1.08

$1.05

Support
$1.02
$0.99
$0.96
Tweet
Growth
Description
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsJohnson & JohnsonInterCeptZoetisBristol-Myers SquibbMylanUltragenyx PharmaceuticalAlkermes